Hans Peter Zenner
Scientific Tracks Abstracts: Transl Med
Molecular personalized medicine has to goal, to identify those patients, who respond in a positive or negative (non-responder, no wanted effect) manner to a specific therapy. Using genomic analyses of the functional proteins otoferlin, connexin26, KCNQ4 or Usher genes personalized plays an increasing role in the indication of cochlear implants for newborn babies. Instead of waiting for a non-development of language, application allows for early implantation and thus for earlier language development.
